340 related articles for article (PubMed ID: 18225576)
21. Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors.
Alshoukr F; Prignon A; Brans L; Jallane A; Mendes S; Talbot JN; Tourwé D; Barbet J; Gruaz-Guyon A
Bioconjug Chem; 2011 Jul; 22(7):1374-85. PubMed ID: 21662976
[TBL] [Abstract][Full Text] [Related]
22. Clinical applications of 68Ga-DOTANOC in neuroendocrine tumours.
Lopci E; Nanni C; Rampin L; Rubello D; Fanti S
Minerva Endocrinol; 2008 Sep; 33(3):277-81. PubMed ID: 18846030
[TBL] [Abstract][Full Text] [Related]
23. Peptide imaging with somatostatin analogues: more than cancer probes.
Cascini GL; Cuccurullo V; Tamburrini O; Rotondo A; Mansi L
Curr Radiopharm; 2013 Mar; 6(1):36-40. PubMed ID: 23470033
[TBL] [Abstract][Full Text] [Related]
24. Somatostatin receptor-based PET/CT of intracranial tumors: a potential area of application for 68 Ga-DOTA peptides?
Sharma P; Mukherjee A; Bal C; Malhotra A; Kumar R
AJR Am J Roentgenol; 2013 Dec; 201(6):1340-7. PubMed ID: 24896203
[TBL] [Abstract][Full Text] [Related]
25. The untapped potential of Gallium 68-PET: the next wave of ⁶⁸Ga-agents.
Smith DL; Breeman WA; Sims-Mourtada J
Appl Radiat Isot; 2013 Jun; 76():14-23. PubMed ID: 23232184
[TBL] [Abstract][Full Text] [Related]
26. The 'double pituitary hot spot' sign of skull base meningioma on gallium-68-labelled somatostatin analogue PET.
Law WP; Fiumara F; Fong W; Macfarlane DJ
J Med Imaging Radiat Oncol; 2013 Dec; 57(6):680-3. PubMed ID: 24283556
[TBL] [Abstract][Full Text] [Related]
27. Positron emission tomography study on pancreatic somatostatin receptors in normal and diabetic rats with 68Ga-DOTA-octreotide: a potential PET tracer for beta cell mass measurement.
Sako T; Hasegawa K; Nishimura M; Kanayama Y; Wada Y; Hayashinaka E; Cui Y; Kataoka Y; Senda M; Watanabe Y
Biochem Biophys Res Commun; 2013 Dec; 442(1-2):79-84. PubMed ID: 24220338
[TBL] [Abstract][Full Text] [Related]
28. Gene transcript analysis blood values correlate with ⁶⁸Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status.
Bodei L; Kidd M; Modlin IM; Prasad V; Severi S; Ambrosini V; Kwekkeboom DJ; Krenning EP; Baum RP; Paganelli G; Drozdov I
Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1341-52. PubMed ID: 25947577
[TBL] [Abstract][Full Text] [Related]
29. [68Ga-DOTA-PET for neuroendocrine tumours].
Loimaala A; Mäenpää H; Lipponen T; Schildt J; Kämäräinen EL; Karhumäki L; Ahonen A
Duodecim; 2014; 130(19):1931-8. PubMed ID: 25558614
[TBL] [Abstract][Full Text] [Related]
30. The Impact of
Cuthbertson DJ; Barriuso J; Lamarca A; Manoharan P; Westwood T; Jaffa M; Fenwick SW; Nuttall C; Lalloo F; Prachalias A; Pizanias M; Wieshmann H; McNamara MG; Hubner R; Srirajaskanthan R; Vivian G; Ramage J; Weickert MO; Pritchard DM; Vinjamuri S; Valle J; Yip VS
Front Endocrinol (Lausanne); 2021; 12():654975. PubMed ID: 34163434
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET.
Fanti S; Ambrosini V; Tomassetti P; Castellucci P; Montini G; Allegri V; Grassetto G; Rubello D; Nanni C; Franchi R
Biomed Pharmacother; 2008 Dec; 62(10):667-71. PubMed ID: 18358680
[TBL] [Abstract][Full Text] [Related]
32. Clinical indications for Gallium-68 positron emission tomography imaging.
Khan MU; Khan S; El-Refaie S; Win Z; Rubello D; Al-Nahhas A
Eur J Surg Oncol; 2009 Jun; 35(6):561-7. PubMed ID: 19201567
[TBL] [Abstract][Full Text] [Related]
33. Radio-guided surgery in neuroendocrine tumors.
Gulec SA; Baum R
J Surg Oncol; 2007 Sep; 96(4):309-15. PubMed ID: 17726664
[TBL] [Abstract][Full Text] [Related]
34. Exceptional increase in somatostatin receptor expression in pancreatic neuroendocrine tumour, visualised with (68)Ga-DOTATOC PET.
Henze M; Schuhmacher J; Dimitrakopoulou-Strauss A; Strauss LG; Mäcke HR; Eisenhut M; Haberkorn U
Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):466. PubMed ID: 14730407
[No Abstract] [Full Text] [Related]
35. [
Giovannini E; Giovacchini G; Borsò E; Lazzeri P; Riondato M; Leoncini R; Duce V; Ciarmiello A
Curr Radiopharm; 2019; 12(1):11-22. PubMed ID: 30539709
[TBL] [Abstract][Full Text] [Related]
36. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE.
Virgolini I; Ambrosini V; Bomanji JB; Baum RP; Fanti S; Gabriel M; Papathanasiou ND; Pepe G; Oyen W; De Cristoforo C; Chiti A
Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):2004-10. PubMed ID: 20596866
[TBL] [Abstract][Full Text] [Related]
37. Contemporary nuclear medicine imaging of neuroendocrine tumours.
Wong KK; Waterfield RT; Marzola MC; Scarsbrook AF; Chowdhury FU; Gross MD; Rubello D
Clin Radiol; 2012 Nov; 67(11):1035-50. PubMed ID: 22633086
[TBL] [Abstract][Full Text] [Related]
38. The present and future role of (111)In pentetreotide in the PET era.
Rambaldi PF; Cuccurullo V; Briganti V; Mansi L
Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):225-35. PubMed ID: 16172568
[TBL] [Abstract][Full Text] [Related]
39. (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives.
Breeman WA; de Blois E; Sze Chan H; Konijnenberg M; Kwekkeboom DJ; Krenning EP
Semin Nucl Med; 2011 Jul; 41(4):314-21. PubMed ID: 21624565
[TBL] [Abstract][Full Text] [Related]
40. Dosimetry of [⁶⁸Ga]-labeled compounds.
Eberlein U; Lassmann M
Appl Radiat Isot; 2013 Jun; 76():70-4. PubMed ID: 22884623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]